RESUMO
Stribild is a compound preparation composed of elvitegravir, cobicistat, emtricitabine and tenofovir. As for the first-treated AIDs patients or re-treated patients with creatinine clearance≥70ml·min-1 , it has definite clinical effect. Owing to once a day, stribild can enhance the acceptability of the patients, and as for the patients treated with other regimen complicated with diarrhea, pain in stomach and numbness in hands and feet, it also provides a good option. However, its adverse effects on kidney, liver and bone density in the long term use should be paid attention.
RESUMO
The efficacy of patients infected with hepatitis C virus complicated with cirrhosis is not promising after treated with present standard therapy. With more and more new drugs against hepatitis C virus, many new regimens for the patients with chronic hepatitis C virus complicated with cirrhosis have come forth. Because the adverse reactions of the first generation HCV protease inhibi-tors telaprevir and boceprevir are severe, they are not recommended to be used in the patients with chronic hepatitis C virus complicated with cirrhosis. The other drugs, such as simeprevir, sofosbuvir and ledipasvir show good efficacy in the patients with chronic hepatitis C virus complicated with cirrhosis, however, the sustained virological response ( SVR) in the patients with chronic hepatitis C virus complicated with cirrhosis is lower than that in the patients with chronic hepatitis C virus without cirrhosis. Therefore, the regimens should be optimized in the future to narrow the gap in SVR.
RESUMO
Referred to the latest literatures on raltegravir from home and abroad, the effect and safety of raltegravir in the treat-ment of AIDs were reviewed. The results showed that raltegravir was a necessary component for the initial treatment and repeated treat-ment of AIDs. Up till now, there was no report on its serious adverse reactions and drug interactions.
RESUMO
The latest literatures on eslicarbazepine acetate in the treatment of epilepsy from home and abroad were referred. The results showed that the oral absorption of eslicarbazepine acetate is quick with long half life, linear pharmacokinetics and low potential of drug-drug interactions. Compared with carbamazepine and oxcarbazepine, eslicarbazepine acetate is more effective against epilepsy.